Properties (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
peptide drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
pre-filled syringe
|
| gptkbp:brand |
gptkb:Gattex
|
| gptkbp:chemicalFormula |
C181H282N44O51S
|
| gptkbp:clinicalTrials |
Phase 3
included in treatment guidelines for short bowel syndrome |
| gptkbp:contraindication |
thromboembolic events
infections gastrointestinal disorders hypersensitivity to the drug history of malignancy |
| gptkbp:developedBy |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:dosageForm |
solution for injection
|
| gptkbp:drugInterdiction |
subcutaneous absorption
GLP-2 analog |
| gptkbp:endOfLife |
approximately 13 hours
|
| gptkbp:financial_aid |
stable for 24 hours at room temperature after reconstitution
|
| gptkbp:hasPopulation |
adults with short bowel syndrome
|
| gptkbp:healthcare |
importance of adherence to therapy
recognizing side effects proper injection technique |
| https://www.w3.org/2000/01/rdf-schema#label |
teduglutide
|
| gptkbp:impact |
long-term therapy
|
| gptkbp:interactsWith |
other medications
|
| gptkbp:is_monitored_by |
nutritional status
hydration status intestinal function |
| gptkbp:issuedBy |
subcutaneous injection
|
| gptkbp:lastProduced |
2012
|
| gptkbp:launchSite |
once daily
|
| gptkbp:lifespan |
improves quality of life
|
| gptkbp:mandates |
patients with intestinal failure
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:numberOfStudents |
primarily renal
|
| gptkbp:nutritionalValue |
improves nutrient absorption
|
| gptkbp:patentExpiration |
2027
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchFocus |
gastrointestinal disorders
peptide therapeutics intestinal adaptation |
| gptkbp:route |
subcutaneous
|
| gptkbp:sideEffect |
fatigue
headache nausea abdominal pain injection site reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:triggerType |
stimulates intestinal growth
|
| gptkbp:usedFor |
treatment of short bowel syndrome
|
| gptkbp:weight |
3960.5 g/mol
|